Association of
+7 (495) 933-7040

Biopharmaceutical company Sobi has become a member of AIPM


July 06, 2022, Moscow – Association of International Pharmaceutical Manufacturers (AIPM) announces extension of the list of members. The biopharmaceutical company Sobi was admitted a member of the AIPM in line with the Statues of the Association following the general vote of the member-companies.

Sobi (Swedish Orphan Biovitrum) is an international biopharmaceutical company specializes in medicines for ultra rare, rare and severe diseases in the areas of hematology and immunology. "Election as the AIPM member is the important step for Sobi. By combining efforts, we are trying to improve interaction with other market participants and partners, which will contribute to the development of the pharmaceutical sector and increase the availability of innovative medicines for patients," - said Vyacheslav Derbizh, General Manager of Sobi in Russia.

Commenting on the decision of the General Meeting, AIPM Executive Director Vladimir Shipkov stressed: "The Association is open to market participants and partners who share our mission and values. Today, only common efforts may lead us to the meaningful goal - to sustain and enhance the availability of high-quality and effective medicines and innovative therapeutic solutions the patients and healthcare system in whole. And realizing our mission, we welcome Sobi as a member of the Association."         


The Association of International Pharmaceutical Manufacturers (AIPM) was established in 1994 and represents in the Russian Federation the leading international pharmaceutical companies - producers and developers of modern effective, safe and high-quality medicines. Today, AIPM unites more than 60 international companies that provide over 80% of the world’s pharmaceutical products and over 60% of medicines imported to the Russian Federation.

For additional information, please contact:

Elena Yankovskaya, PR & Communications Director, AIPM

About Sobi:

Sobi (Swedish Orphan Biovitrum) is a Swedish international biopharmaceutical company focused on rare diseases. Sobi provides sustainable access to innovative treatments in the areas of hematology and immunology. The company has been represented in Russia since 2008.

More detailed information about the company can be found on the website

For additional information, please contact:

Lara Nevolina, Government Affairs & Patient Access Director, Sobi Russia